The Generics Bulletin Top 50, Part Three: Newcomers Climb Into Bottom Table
As Some Firms Disappear From The Ranking This Year, Others Fill Their Places
In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.
You may also be interested in...
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.
Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.